A newly-developed drug that targets a key cell survival pathway could be used to slow the progression of lymphoma.
Scientists at the Institute of Oncology Research (IOR) in Switzerland investigated the effectiveness of PQR309 (bimiralisib), an inhibitor of the PI3K/AKT/mTOR pathway, in blocking the growth of lymphoma cells.
PI3K inhibitor, idelasib, is already approved to clinical use but many patients do not respond to the treatment. However, whereas idelasib only blocks one component of this pathway, the novel drug targets multiple stages of the axis.
The study, which included preclinical screening of multiple cell lines and in vivo models, demonstrated the efficacy of the drug both alone and combination with other drugs. Importantly, bimiralisib showed anti-tumour activity in cells resistant to idelasib.
Publishing in Clinical Cancer Research, the authors conclude that the drug could constitute a promising new treatment for lymphoma.
Source: Tarantelli C, Gaudio E, Arribas AJ et al. PQR309 is a novel dual PI3K/mTOR inhibitor with pre-clinical antitumor activity in lymphomas as a single agent and in combination therapy. Clinical Cancer Research. 24 October 2017; doi: 10.1158/1078-0432.CCR-17-1041
Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.
News service provided by Englemed News http://www.englemed.co.uk/